Heat Biologics is a clinical-stage company focused on developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers.
The Company's ImPACT therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. ImPACT effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. This therapy is applicable to a wide range of cancers.
Heat is currently conducting multiple clinical trials in two indications with its ImPACT therapy based products, HS-410 to treat Non-Muscle Invasive Bladder Cancer (NMIBC) and HS-110 to treat Non-Small Cell Lung Cancer (NSCLC).

TypePublic
HQDurham, US
Founded2008
Size (employees)19 (est)
Websiteheatbio.com
Heat Biologics was founded in 2008 and is headquartered in Durham, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Heat Biologics

Jeffrey Wolf

Jeffrey Wolf

Founder and CEO
Jeff Hutchins

Jeff Hutchins

Chief Scientific and Operating Officer
George Peoples

George Peoples

Chief Medical Advisor
Ann A. Rosar

Ann A. Rosar

Vice President of Finance, Corporate Secretary
Janice Marie McCourt

Janice Marie McCourt

Vice President, Business Development
Lori McDermott

Lori McDermott

Vice President, Clinical Development
Show more

Heat Biologics Office Locations

Heat Biologics has an office in Durham
Durham, (HQ)
12 801 Capitola Dr
Show all (1)
Report incorrect company information

Heat Biologics Financials and Metrics

Heat Biologics Revenue

Heat Biologics's revenue was reported to be $341.64 k in FY, 2016
USD

Net income (Q3, 2018)

(3.9m)

EBIT (Q3, 2018)

(4.3m)

Market capitalization (4-Dec-2018)

45.4m

Closing stock price (4-Dec-2018)

1.4

Cash (30-Sep-2018)

21.0m
Heat Biologics's current market capitalization is $45.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

341.6k

General and administrative expense

2.4m4.0m4.4m4.1m6.4m

R&D expense

2.7m2.9m2.6m9.3m8.3m

Operating expense total

6.6m6.8m21.0m13.5m14.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

220.2k24.2k

General and administrative expense

1.0m1.0m832.1k1.3m893.2k947.4k1.0m1.1m820.6k1.5m1.6m1.2m1.8m1.4m1.6m

R&D expense

992.4k533.6k849.4k1.0m503.6k587.2k677.2k500.2k454.9k559.2k1.8m2.2m1.8m2.9m3.5m4.4m

Operating expense total

2.0m2.4m1.9m3.1m1.8m4.9m5.3m4.7m2.9m2.5m3.3m3.7m3.0m4.7m5.4m6.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

4.6m3.7m4.9m7.8m9.8m

Accounts Receivable

1.8m82.3k14.8k

Inventories

1.7m

Current Assets

23.0m15.3m12.5m8.3m11.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

23.6m2.7m6.0m3.3m10.3m11.5m8.2m10.0m7.1m8.5m11.1m8.3m4.3m9.0m24.7m21.0m

Accounts Receivable

131.8k2.0k10.0k1.4k5.4k14.3k68.2k

Current Assets

24.4m20.3m17.6m16.1m22.2m20.2m15.9m12.5m7.6m9.1m11.4m8.6m6.2m10.6m28.7m23.5m

PP&E

13.1k56.7k480.9k464.3k428.2k495.0k468.0k444.4k423.7k392.9k332.0k308.2k320.0k662.0k645.7k663.1k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(6.6m)(12.2m)(21.1m)(13.0m)(12.4m)

Depreciation and Amortization

6.3k66.9k116.0k132.1k134.1k

Inventories

10.0k

Accounts Payable

146.4k642.0k(1.7m)(175.9k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(4.5m)(2.4m)(3.0m)(8.5m)(4.0m)(8.9m)(14.4m)(4.7m)(7.8m)(9.4m)(3.2m)(6.5m)(9.1m)(3.7m)(8.0m)(11.5m)

Depreciation and Amortization

2.9k2.2k41.9k25.6k53.9k84.4k32.4k65.6k98.8k33.1k66.7k101.0k44.1k108.4k171.2k

Accounts Payable

(112.9k)(273.5k)720.1k28.6k(555.6k)(570.0k)(385.2k)(494.3k)(1.5m)(1.5m)442.0k(202.2k)4.2k667.6k(211.9k)(55.4k)

Cash From Operating Activities

(4.8m)(2.4m)(7.3m)(4.5m)(8.2m)(12.4m)(4.9m)(8.9m)(10.8m)(3.0m)(5.4m)(9.4m)(3.8m)(11.8m)(15.7m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Heat Biologics Online and Social Media Presence

Embed Graph
Report incorrect company information

Heat Biologics Blogs

Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offeringwdxefcqufszuzezftuxetqsqxt

DURHAM, NC / ACCESSWIRE / November 26, 2018 / Heat Biologics, Inc. (''Heat'') (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced the closing of its previously announced underwritten public offering of 8,000,000 …

Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum

DURHAM, NC / ACCESSWIRE / November 26, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has been invited to participate in a panel presentation, entitled Gene &Cell …

Heat Biologics, Inc. Prices $12,000,000 Public Offering

DURHAM, NC / ACCESSWIRE / November 21, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation, today announced the pricing of an underwritten public off…

Heat Biologics, Inc. Announces Proposed Public Offering

DURHAM, NC / ACCESSWIRE / November 20, 2018 / HEATBIOLOGICS, INC. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation, today announced that it intends to offer for sale its common stock …

Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update

On track to report key clinical milestones beginning in Q4 2018 DURHAM,NC / ACCESSWIRE / November 15, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today reported financial and clinical up…

Heat Biologics to Present at Precision: Lung Cancer World R&D Summit

DURHAM, NC /ACCESSWIRE / October 22, 2018 / HeatBiologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced that Jeff Hutchins, Ph.D. Chief Scientific and Operating Officer, plans to present "The Clinical…
Show more

Heat Biologics Company Life and Culture

Report incorrect company information

Heat Biologics Frequently Asked Questions

  • When was Heat Biologics founded?

    Heat Biologics was founded in 2008.

  • Who are Heat Biologics key executives?

    Heat Biologics's key executives are Jeffrey Wolf, Jeff Hutchins and George Peoples.

  • How many employees does Heat Biologics have?

    Heat Biologics has 19 employees.

  • Who are Heat Biologics competitors?

    Competitors of Heat Biologics include Aptevo Therapeutics, Cleveland BioLabs and Aeglea Biotherapeutics.

  • Where is Heat Biologics headquarters?

    Heat Biologics headquarters is located at 12 801 Capitola Dr, Durham.

  • Where are Heat Biologics offices?

    Heat Biologics has an office in Durham.

  • How many offices does Heat Biologics have?

    Heat Biologics has 1 office.